| 000 | 01877 a2200505 4500 | ||
|---|---|---|---|
| 005 | 20250513084335.0 | ||
| 264 | 0 | _c19960223 | |
| 008 | 199602s 0 0 eng d | ||
| 022 | _a0732-183X | ||
| 024 | 7 |
_a10.1200/JCO.1996.14.1.142 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aMillward, M J | |
| 245 | 0 | 0 |
_aPhase II trial of a 3-hour infusion of paclitaxel in previously untreated patients with advanced non-small-cell lung cancer. _h[electronic resource] |
| 260 |
_bJournal of clinical oncology : official journal of the American Society of Clinical Oncology _cJan 1996 |
||
| 300 |
_a142-8 p. _bdigital |
||
| 500 | _aPublication Type: Clinical Trial; Clinical Trial, Phase II; Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't | ||
| 650 | 0 | 4 | _aAdult |
| 650 | 0 | 4 | _aAged |
| 650 | 0 | 4 |
_aCarcinoma, Non-Small-Cell Lung _xdrug therapy |
| 650 | 0 | 4 | _aConfidence Intervals |
| 650 | 0 | 4 | _aDisease-Free Survival |
| 650 | 0 | 4 |
_aDrug Hypersensitivity _xetiology |
| 650 | 0 | 4 | _aFemale |
| 650 | 0 | 4 |
_aHematologic Diseases _xchemically induced |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 | _aInfusions, Intravenous |
| 650 | 0 | 4 |
_aLung Neoplasms _xdrug therapy |
| 650 | 0 | 4 | _aMale |
| 650 | 0 | 4 | _aMiddle Aged |
| 650 | 0 | 4 |
_aNervous System Diseases _xchemically induced |
| 650 | 0 | 4 |
_aPaclitaxel _xadministration & dosage |
| 650 | 0 | 4 | _aSurvival Rate |
| 650 | 0 | 4 | _aTreatment Outcome |
| 700 | 1 | _aBishop, J F | |
| 700 | 1 | _aFriedlander, M | |
| 700 | 1 | _aLevi, J A | |
| 700 | 1 | _aGoldstein, D | |
| 700 | 1 | _aOlver, I N | |
| 700 | 1 | _aSmith, J G | |
| 700 | 1 | _aToner, G C | |
| 700 | 1 | _aRischin, D | |
| 700 | 1 | _aBell, D R | |
| 773 | 0 |
_tJournal of clinical oncology : official journal of the American Society of Clinical Oncology _gvol. 14 _gno. 1 _gp. 142-8 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1200/JCO.1996.14.1.142 _zAvailable from publisher's website |
| 999 |
_c8557262 _d8557262 |
||